TuesdayFeb 13, 2024 2:35 pm

TinyGemsBreaks — Vision Marine Technologies Inc. (NASDAQ: VMAR) Names MarineMax Executive to Board

Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator within the performance electric recreational boating industry, announced that Anthony E. Cassella Jr., executive vice president finance and chief accounting officer at MarineMax Inc. (NYSE: HZO) has been appointed to its board of directors; Cassella will serve as an independent director. According to the announcement, the appointment reflects VMAR’s leading role in marine technology innovation and underscores its commitment to strong corporate governance; the company noted that the veteran’s background and industry knowledge “will bring incredible value to the next chapter of Vision Marine's mission to become the leading provider…

Continue Reading

TuesdayFeb 13, 2024 2:09 pm

TinyGemsBreaks – GEMXX Corp. (GEMZ) Announces Groundbreaking Start for January Product Deliveries

GEMXX (OTC: GEMZ), a pioneering mine-to-market gold, gemstone and jewelry producer, today announced a stellar start to the year with impressive product deliveries worth $1,051,374 at retail for the month of January. According to the announcement, January’s deliveries mark an incredible 600% increase compared to the same period last year, highlighting GEMXX's strong growth trajectory and its effective business strategies. “Our January delivery results are a testament to the hard work and dedication of the GEMXX team,” said Jay Maull, CEO of GEMXX Corporation. “Our ability to achieve such significant deliveries is a clear indication of our competitive edge in…

Continue Reading

MondayFeb 12, 2024 3:34 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 Drug to Bloodstream

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced the final results from its completed human Pilot Study #1 that sought to evaluate the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially in the branded product Rybelsus(R). “Most notable from its pilot study was the improved delivery of semaglutide to the bloodstream, which significantly improved blood sugar control. For one, in just 20 minutes after oral administration, the DehydraTECH-GLP-1 blood semaglutide level was about 261% higher than that of the control, a statistic that reflected…

Continue Reading

FridayFeb 09, 2024 1:25 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chief financial officer and corporate secretary, effective Feb. 20, 2024. Jagpal has garnered more than two decades of experience in financial leadership roles, primarily in the biotech industry. Most recently, she was vice president of Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS), where she was a key player in the company’s initial public offering process;…

Continue Reading

ThursdayFeb 08, 2024 2:03 pm

TinyGemsBreaks — Diamond Lake Minerals Inc. (DLMI) CEO Talks Commitment to Regulation, Discusses Vision for Real Estate Tokenization

Diamond Lake Minerals (OTC: DLMI), a leading player in the digital asset landscape bridging the gap between traditional finance and decentralized finance, is featured in a recent interview released from Proactive. During the interview, Diamond Lake Minerals CEO Brian J. Esposito talks with Proactive host Steve Darling about the company’s distinctive approach to digital assets. During the interview, Esposito explained that Diamond Lake Minerals focuses on security token offerings (“STOs”) within a regulated environment, which is distinctive from unregulated cryptocurrencies and represents the company’s commitment to regulatory compliance and security. Esposito also noted that Diamond Lakes places a high priority on transparency…

Continue Reading

WednesdayFeb 07, 2024 2:58 pm

TinyGemsBreaks – GEMXX Corp. (GEMZ) Continues to Enhance Long-Term Asset Expansion Plan

GEMXX (OTC: GEMZ) is a mine-to-market company that focuses on producing gold, gemstone and jewelry from its own land resources. GEMXX last year acquired a 50% interest in Crazy Horse Mining Inc. (“CHMI”), a Canadian exploration company that owns 100% interest in two gold projects in British Columbia (Snow Creek and Rosella Creek), as well as signed a binding letter of intent to acquire a 50% interest in the historic Yukon Gold Project, which holds 2,210,660 ounces of proven gold resources. “The acquisition [of the Yukon Gold Project] is pending, awaiting the completion of due diligence and verification of the…

Continue Reading

WednesdayFeb 07, 2024 2:22 pm

TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications. According to the announcement, the company is expanding through sponsored research agreements and material transfer agreements with several academic research collaborators. The programs will be focused on studying TUSC2, the tumor suppressor gene used in Genprex's lead drug candidate, REQORSA(R) (quaratusugene ozeplasmid), and NPRL2, another tumor suppressor gene. The company noted that new indications being evaluated include ALK-positive lung cancer as well as additional undisclosed programs. The expanded programs comprise research being conducted…

Continue Reading

TuesdayFeb 06, 2024 3:32 pm

TinyGemsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Disrupting Traditional Boating Industry with Electric Power

Vision Marine Technologies Inc. (NASDAQ: VMAR) is dedicated to pioneering the clean-energy transition on the water. “Boating magazine announced its Boat of the Year category winners for 2023, and the Four Winns H2e came out on top in the Runabout category. The Four Winns bowrider is powered by Vision Marine Technologies’ E-Motion, a 180 HP electric onboard engine that is the most powerful marine electric powertrain in the world,” a recent article reads. “The Four Winns H2e E-Motion engine is only a small piece of what VMAR does. As the global leader in the electric recreational boating industry serving both…

Continue Reading

TuesdayFeb 06, 2024 2:35 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces Bollinger’s Receipt of IRS Approval for $40K Commercial EV Tax Credit

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that Bollinger Motors (“Bollinger”) has received IRS approval as a “qualified manufacturer” for clean vehicle credits under the Inflation Reduction Act of 2022 (the “IRA”). According to the announcement, the designation enables the Bollinger B4 chassis cab to qualify for the IRA’s new credit for qualified commercial clean vehicles, providing eligible purchasers a tax credit of up to $40,000 per vehicle. “Bollinger Motors is poised for growth and we’re ready to help electrify America’s fleets,” said Robert Bollinger, founder and CEO of Bollinger Motors. “These tax credits are…

Continue Reading

TuesdayFeb 06, 2024 12:23 pm

TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City. According to the company, CFO Ryan Confer will present at the two-day event. His presentation, which will begin at 1:30 p.m. ET on Feb. 26, will include an overview of the company's gene therapies for cancer and diabetes; Confer will also be available for in-person, one-on-one meetings with investors through the conference platform. To view the full press release,…

Continue Reading

Contact us: (512) 354-7000